Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>We analyzed the post-announcement return pattern of MS-Japan rebalance stocks in the context of past MSCI Japan cycles.</li>
<li>DELETE: 14 names averaged -5.3% WPreA alpha before announcement; all 14 negative; flat on WAI Day 1. </li>
<li>ADD: All three stocks ran +18-21% WPreA alpha before announcement. WAI Day 1 returns split by velocity group. Historical ADD WAI alpha is mixed across prior cycles.</li>
</ul>


We analyzed the post-announcement return pattern of MS-Japan rebalance stocks in the context of past MSCI Japan cycles.
DELETE: 14 names averaged -5.3% WPreA alpha before announcement; all 14 negative; flat on WAI Day 1. 
ADD: All three stocks ran +18-21% WPreA alpha before announcement. WAI Day 1 returns split by velocity group. Historical ADD WAI alpha is mixed across prior cycles.


MS-Japan May 2026 Rebalance: Post-Announcement Trading Pattern

Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>M3 operates a dominant digital platform for healthcare professionals in Japan, creating a strong network effect and a significant competitive advantage. Its core business benefits from the ongoing digitalization of pharmaceutical marketing.</li>
  <li>Recent financial performance has been characterized by consistent revenue growth, but significant margin compression and a decline in net income. This is attributed to the normalization of business post-COVID-19 and increased costs associated with new ventures.</li>
  <li>The company is pursuing growth through overseas expansion and strategic M&amp;A, diversifying its revenue streams into areas like clinical trial support and career solutions. However, the market has reacted negatively to recent performance, leading to a substantial stock price decline.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  M3 operates a dominant digital platform for healthcare professionals in Japan, creating a strong network effect and a significant competitive advantage. Its core business benefits from the ongoing digitalization of pharmaceutical marketing.
  Recent financial performance has been characterized by consistent revenue growth, but significant margin compression and a decline in net income. This is attributed to the normalization of business post-COVID-19 and increased costs associated with new ventures.
  The company is pursuing growth through overseas expansion and strategic M&amp;A, diversifying its revenue streams into areas like clinical trial support and career solutions. However, the market has reacted negatively to recent performance, leading to a substantial stock price decline.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Japanese Equity Specialist, Ortus Advisors

Andrew Jackson

Japanese Equity Specialist

Ortus Advisors

Kawasaki Heavy Industries / Equity Bottom-Up

<ul>
<li>Expect continued buying in defense related, as well as banks and life insurance, renewable energy, rails, and medical IT plays with Shigeru Ishiba at the helm. </li>
<li>The Market will be quick to rotate out of names which spiked into Friday's close on expectation for a Sanae Takaichi win in the LDP election.  </li>
<li>Ishiba has been a vocal critic of Abenomics, and his potential policies aimed at higher taxes for investment incomes and capital gains are set to weigh on the Japanese market. </li>
</ul>


Expect continued buying in defense related, as well as banks and life insurance, renewable energy, rails, and medical IT plays with Shigeru Ishiba at the helm. 
The Market will be quick to rotate out of names which spiked into Friday's close on expectation for a Sanae Takaichi win in the LDP election.  
Ishiba has been a vocal critic of Abenomics, and his potential policies aimed at higher taxes for investment incomes and capital gains are set to weigh on the Japanese market. 


Best Outright and Pair Trades for an Ishiba-Led LDP

Japan Specialist

Mark Chadwick

Thematic (Sector/Industry)

<ul>
<li>Japan's tech market sees major movement with Carlyle's 120% premium bid for Kaonavi, highlighting the stark valuation gap between Japanese and US SaaS companies.</li>
<li>Many Japanese software firms trade at significantly lower multiples (4x) versus US peers (8x), attracting private equity attention.</li>
<li>Japanese stocks ended the week up around 1%. Global macro concerns and inflation lifting bond yields and raising concern over a stronger yen. </li>
</ul>


Japan's tech market sees major movement with Carlyle's 120% premium bid for Kaonavi, highlighting the stark valuation gap between Japanese and US SaaS companies.
Many Japanese software firms trade at significantly lower multiples (4x) versus US peers (8x), attracting private equity attention.
Japanese stocks ended the week up around 1%. Global macro concerns and inflation lifting bond yields and raising concern over a stronger yen. 


Japan Strategy Weekly | Carlyle's Kaonavi Deal Signals a Shift in Japanese Valuations

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Today, the day before the previously extended <a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a> Partial Tender Offer for <a href="https://www.smartkarma.com/entities/benefit-one-inc" target="_blank" data-smartkarma-citation="entities:14502:1" rel="noopener">Benefit One Inc (2412 JP)</a> was due to expire, M3 extended it another 20 days.</li>
<li>
<a href="https://www.smartkarma.com/entities/dai-ichi-life-insurance" target="_blank" data-smartkarma-citation="entities:1109:1" rel="noopener">Dai Ichi Life Insurance (8750 JP)</a> several days ago extended their expected start date by weeks - from mid-January to early February. </li>
<li>The wording in the new <a href="https://corporate.m3.com/assets.ctfassets.net/1pwj74siywcy/4uecKStlttjhRmZYyPSB6C/944bc5119e67c0b1780c24aac8936476/Public_E_20240116.pdf" target="_blank" rel="noopener">document</a> from M3 is curious. It bears examination. As does the strategy positioning and choice of each of the participants. </li>
</ul>


Today, the day before the previously extended M3 Inc (2413 JP) Partial Tender Offer for Benefit One Inc (2412 JP) was due to expire, M3 extended it another 20 days.

Dai Ichi Life Insurance (8750 JP) several days ago extended their expected start date by weeks - from mid-January to early February. 
The wording in the new document from M3 is curious. It bears examination. As does the strategy positioning and choice of each of the participants. 


Japan

M3, Inc. supplies medical information services for doctors through the Internet. The Company also supports marketing of pharmaceutical companies and medical equipment manufacturers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

M3 Inc (2413 JP)

MS-Japan May 2026 Rebalance: Post-Announcement Trading Pattern

Following MSCI May 2026 announcement, we a look at the trading pattern of affected stocks from historical perspective by overlaying it with past...

Ke Yan, CFA, FRM

Primer: M3 Inc (2413 JP) - May 2026

M3 operates a dominant digital platform for healthcare professionals in Japan, creating a strong network effect and a significant competitive...

αSK

Best Outright and Pair Trades for an Ishiba-Led LDP

How to position in Japanese equities after the surprise win by Shigeru Ishiba over Sanae Takaichi in Friday's LDP election.

Andrew Jackson

Japan Strategy Weekly | Carlyle's Kaonavi Deal Signals a Shift in Japanese Valuations

Carlyle's bid for Kaonavi underscores valuation gap between Japanese and US SaaS companies, attracting private equity interest. Japanese stocks up...

Mark Chadwick

Benefit One (2412): The Plot Thickens

Dai-Ichi Life extended its "expected Tender launch" by a couple of weeks about 5 days ago. That went past M3's TOB end. BenefitOne asked them to...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

MS-Japan May 2026 Rebalance: Post-Announcement Trading Pattern

Following MSCI May 2026 announcement, we a look at the trading pattern of affected stocks from historical perspective by overlaying it with past...

Ke Yan, CFA, FRM

Primer: M3 Inc (2413 JP) - May 2026

M3 operates a dominant digital platform for healthcare professionals in Japan, creating a strong network effect and a significant competitive...

αSK

Best Outright and Pair Trades for an Ishiba-Led LDP

How to position in Japanese equities after the surprise win by Shigeru Ishiba over Sanae Takaichi in Friday's LDP election.

Andrew Jackson

Japan Strategy Weekly | Carlyle's Kaonavi Deal Signals a Shift in Japanese Valuations

​Carlyle's bid for Kaonavi underscores valuation gap between Japanese and US SaaS companies, attracting private equity interest. Japanese stocks up...

Mark Chadwick

Benefit One (2412): The Plot Thickens

Dai-Ichi Life extended its "expected Tender launch" by a couple of weeks about 5 days ago. That went past M3's TOB end. BenefitOne asked them to...

Travis Lundy

Carlyle's bid for Kaonavi underscores valuation gap between Japanese and US SaaS companies, attracting private equity interest. Japanese stocks up...